| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f53612b4d41a1422cc946997ae20bdbb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-64 |
| filingDate |
1992-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_294be301023cb17529084dfc52debf73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_433a8d34c8013c6baaddd543dc3bac87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f529dd3bdd3693ce06151a3af0a9cfa7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e58c2929490f9240d3bbc35c6c103ff |
| publicationDate |
2002-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0593585-B1 |
| titleOfInvention |
Peptide which abrogates tnf and lps toxicity |
| abstract |
The present invention provides peptides which have the ability to abrogate TNF toxicity and/or LPS toxicity. The present invention further relates to compositions including these peptides as the active ingredient and methods of anti-inflammatory treatment involving the administration of this composition. The peptides of the present invention are based primarily on residue 1 to 26 of human TNF. |
| priorityDate |
1991-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |